title: Spondyloarthropathies: an independent cardiovascular risk factor?
abstract: An increase in cardiovascular mortality and morbidity has been convincingly documented in rheumatoid arthritis. Data on spondyloarthropathies are more limited. Here, we discuss published studies indicating that patients with spondyloarthropathies are at increased risk for cardiovascular disease. The excess risk is probably multifactorial, being related both to chronic systemic inflammation and to high prevalences of conventional cardiovascular risk factors. Cardiovascular risk management in patients with spondyloarthropathies requires optimal control of disease activity combined with interventions targeting conventional cardiovascular risk factors.
authors.affiliation: Service de rhumatologie, CHU Gabriel-Montpied, 58, rue Montalembert, 63003 Clermont-Ferrand, France. smathieu11@yahoo.fr
authors.forename: Sylvain
authors.initials: S
authors.lastname: Mathieu
authors.forename: Pascal
authors.initials: P
authors.lastname: Motreff
authors.forename: Martin
authors.initials: M
authors.lastname: Soubrier
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects; D015535:Arthritis, Psoriatic / Q000188:drug therapy / Q000453:epidemiology; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000453:epidemiology* / Q000517:prevention & control; D015897:Comorbidity; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects; D005260:Female; D006801:Humans; D008019:Life Style; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D025242:Spondylarthropathies / Q000188:drug therapy / Q000453:epidemiology*; D013167:Spondylitis, Ankylosing / Q000188:drug therapy / Q000453:epidemiology; D015996:Survival Rate
chemical_list: D000924:Anticholesteremic Agents; D018501:Antirheumatic Agents; D052246:Cyclooxygenase 2 Inhibitors